Pharmaceutical executive brings extensive M&A experience to support the company’s continued growth plans
Mississauga, ON: October 21, 2021. MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that seasoned pharmaceutical finance executive Lesley Bourget has been appointed as the Company’s Chief Financial Officer (“CFO”), effective November 8th, 2021.
With more than 30 years’ experience in health-care, pharmaceutical and CPG industries, Ms. Bourget has a proven track record for profit generation by successfully leading product portfolio optimization efforts, negotiating large-scale acquisitions, and conceiving and implementing mergers in the R&D space. Ms. Bourget most recently served as CFO of Aspen Pharmacare Canada, where she was instrumental in achieving company-record profit levels, and optimizing inventory and wholesaler processes. Ms. Bourget’s appointment will further support MedX’s global commercialization strategy, as the Company seeks to build on the momentum of current commercial and product distribution pilots underway across North America and Europe, with additional pilots anticipated in the coming months.
Ms. Bourget holds the professional designation of Certified Management Accountant (CPA, CMA) and is qualified in International Financial Reporting through an IFRS Certification (CMA).
“On behalf of MedX’s Board of Directors and leadership team, I want to warmly welcome Lesley as she takes on the pivotal CFO role during a time of rapid growth for our Company,” said Sylvain Desjeans, MedX President and CEO. “Lesley is an inspirational and visionary leader, with a long track record of supporting market growth through her extensive M&A negotiation and alliance-building experience for public pharmaceutical and health care companies. I look forward to working with Lesley to further harness MedX’s growth opportunities ahead.”
On her CFO appointment, Lesley Bourget commented, “I was drawn to MedX due to its mission of saving lives and its technology’s unique ability to make teledermatology accessible for patients around the world. Strengthening virtual health-care services has never been more important than it is now, amid a global pandemic. I feel privileged to join the MedX team to help fulfill its growth potential and improve patient outcomes.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – both patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. MedX’s DermSecure® Screening Platform then transmits these high-resolution images safely and securely for virtual dermatological assessment by a certified dermatologist within just 72 hours, compared to a wait time of up to 90 days for traditional dermatological assessment.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485-certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are approved by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Bill Mitoulas, Investor Relations
MedX Health Corp.